Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2006 1
2007 4
2008 1
2009 1
2013 1
2020 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.
Komori M, Nogimori T, Morey AL, Sekida T, Ishimoto K, Hassett MR, Masuta Y, Ode H, Tamura T, Suzuki R, Alexander J, Kido Y, Matsuda K, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Akahata W. Komori M, et al. Among authors: smith jf. Nat Commun. 2023 May 19;14(1):2810. doi: 10.1038/s41467-023-38457-x. Nat Commun. 2023. PMID: 37208330 Free PMC article.
Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.
Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, Kazami Y, Washizaki A, Masuta Y, Suzuki R, Matsuda K, Komori M, Morey AL, Ishimoto K, Nakata M, Hasunuma T, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Sato N. Akahata W, et al. Among authors: smith jf. Cell Rep Med. 2023 Aug 15;4(8):101134. doi: 10.1016/j.xcrm.2023.101134. Cell Rep Med. 2023. PMID: 37586325 Free PMC article. Clinical Trial.
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine.
Aboshi M, Matsuda K, Kawakami D, Kono K, Kazami Y, Sekida T, Komori M, Morey AL, Suga S, Smith JF, Fukuhara T, Iwatani Y, Yamamoto T, Sato N, Akahata W. Aboshi M, et al. Among authors: smith jf. iScience. 2024 Jan 22;27(2):108964. doi: 10.1016/j.isci.2024.108964. eCollection 2024 Feb 16. iScience. 2024. PMID: 38352232 Free PMC article.
Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, Wagner J, Watson A, Negri S, Burnett BK, Graham A, Smith JF, Chulay JD. Hubby B, et al. Among authors: smith jf. Vaccine. 2007 Nov 23;25(48):8180-9. doi: 10.1016/j.vaccine.2007.09.038. Epub 2007 Oct 5. Vaccine. 2007. PMID: 17961878 Free PMC article.
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.
Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM. Herbert AS, et al. Among authors: smith jf. J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13. J Virol. 2013. PMID: 23408633 Free PMC article.
A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
Thoresen D, Matsuda K, Urakami A, Ngwe Tun MM, Nomura T, Moi ML, Watanabe Y, Ishikawa M, Hau TTT, Yamamoto H, Suzaki Y, Ami Y, Smith JF, Matano T, Morita K, Akahata W. Thoresen D, et al. Among authors: smith jf. J Virol. 2024 Apr 22:e0023924. doi: 10.1128/jvi.00239-24. Online ahead of print. J Virol. 2024. PMID: 38647327
19 results